Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AXLA

AXLA - Axcella Health Inc Stock Price, Fair Value and News

0.40USD Market Closed
Watchlist

Market Summary

USD0.40
Market Closed

AXLA Stock Price

View Fullscreen

AXLA RSI Chart

AXLA Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

8.48

Price/Free Cashflow

-0.03

AXLA Price/Sales (Trailing)

AXLA Profitability

Return on Equity

-11.39%

Return on Assets

-519.61%

Free Cashflow Yield

-3.4K%

AXLA Fundamentals

AXLA Revenue

Revenue (TTM)

139.0K

Rev. Growth (Yr)

103.08%

Rev. Growth (Qtr)

-5.71%

AXLA Earnings

Earnings (TTM)

-48.2M

Earnings Growth (Yr)

83.98%

Earnings Growth (Qtr)

14.16%

Breaking Down AXLA Revenue

Last 7 days

-20%

Last 30 days

-87.5%

Last 90 days

-96.2%

Trailing 12 Months

-94.9%

How does AXLA drawdown profile look like?

AXLA Financial Health

Current Ratio

0.8

AXLA Investor Care

Shares Dilution (1Y)

39.99%

Diluted EPS (TTM)

-18.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
2021264.3K222.5K180.8K139.0K
20201.4M1.1M683.0K306.0K
2019863.8K1.2M1.5M1.8M
2018000547.0K

Tracking the Latest Insider Buys and Sells of Axcella Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 01, 2023
koziel margaret
sold
-393
0.58
-679
chief medical officer
Feb 10, 2023
fehlner paul
acquired
3,446
0.6602
5,221
svp & chief legal officer
Oct 19, 2022
hinshaw william
sold
-25,027
1.5642
-16,000
president & ceo
Oct 17, 2022
hinshaw william
acquired
-
-
50,000
president & ceo
Oct 13, 2022
societe des produits nestle s.a.
bought
6,000,010
1.64
3,658,540
-
Oct 13, 2022
flagship ventures fund iv general partner llc
bought
5,000,000
1.64
3,048,780
-
Oct 13, 2022
flagship ventures fund iv general partner llc
bought
9,022,020
1.64
5,501,230
-
Oct 13, 2022
flagship ventures fund iv general partner llc
bought
3,007,340
1.64
1,833,740
-
Sep 06, 2022
koziel margaret
sold
-1,378
2.5195
-547
chief medical officer
Jun 01, 2022
koziel margaret
sold
-1,186
2.0107
-590
chief medical officer

1–10 of 50

Which funds bought or sold AXLA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-271
-
-%
Feb 14, 2024
Schonfeld Strategic Advisors LLC
sold off
-100
-1,050,260
-
-%
Feb 14, 2024
Flagship Pioneering Inc.
sold off
-100
-12,215,400
-
-%
Feb 14, 2024
HarbourVest Partners LLC
sold off
-100
-2,592,430
-
-%
Feb 14, 2024
VANGUARD GROUP INC
sold off
-100
-334,442
-
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-3,000
-
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
sold off
-100
-115,103
-
-%
Feb 13, 2024
MORGAN STANLEY
sold off
-100
-10,482
-
-%
Feb 13, 2024
FMR LLC
sold off
-100
-693,790
-
-%

1–10 of 20

Are Funds Buying or Selling AXLA?

Are funds buying AXLA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXLA
No. of Funds

Unveiling Axcella Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 11, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
harbourvest partners l.p.
8.4%
6,207,929
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 02, 2023
societe des produits nestle s.a.
15.09%
11,105,438
SC 13G/A
Oct 17, 2022
flagship venturelabs iv, llc
2.8%
2,035,830
SC 13D/A
Sep 23, 2022
flagship venturelabs iv, llc
3.9%
2,035,830
SC 13D/A
Mar 29, 2022
harbourvest partners l.p.
8.46%
4,378,661
SC 13G/A
Mar 18, 2022
flagship venturelabs iv, llc
3.9%
2,035,830
SC 13D/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 16, 2021
harbourvest partners l.p.
7.5%
2,807,981
SC 13G/A

Recent SEC filings of Axcella Health Inc

View All Filings
Date Filed Form Type Document
Feb 15, 2024
25-NSE
25-NSE
Dec 22, 2023
8-K
Current Report
Dec 19, 2023
8-K
Current Report
Dec 04, 2023
8-K
Current Report
Nov 17, 2023
S-8 POS
Employee Benefits Plan
Nov 17, 2023
S-8 POS
Employee Benefits Plan
Nov 17, 2023
DEF 14A
DEF 14A
Nov 17, 2023
8-K
Current Report

Peers (Alternatives to Axcella Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Axcella Health Inc News

Latest updates
Marketscreener.com30 Dec 202304:14 am
Proactive Investors UK5 months ago

Axcella Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-5.7%13214011590.0065.0022.0031.0039.0048.0035.0029.0024.0018.00257290324357390-
Operating Expenses-15.3%3,5434,18320,94617,09320,61918,33017,20314,90315,24414,49614,46711,72513,18414,46015,34016,99714,07111,0319,163
  S&GA Expenses-15.7%2,3192,7503,5003,7763,7534,7864,7364,7734,9464,2563,8694,1844,6194,1252,7454,8404,7283,4681,286
  R&D Expenses-14.6%1,2241,43313,25713,31716,86613,54412,46710,13010,29810,24010,5987,5418,56510,33512,59512,1579,3437,5637,877
Interest Expenses---1,1466756275731,1905905715661,875-712-7086693,326-307-3768814,405
Net Income14.2%-3,413-3,976-23,000-17,841-21,306-19,039-17,891-15,613-15,935-15,189-15,189-12,437-13,892-15,009-15,713-17,304-14,447-11,573-9,762
Net Income Margin27.1%-346.98*-475.71*-584.07*-547.32*-531.29*-492.65*-464.95*-342.61*-264.04*-214.60*-184.73*-83.53*-58.41*------
Free Cashflow-72.5%-8,800-5,100-15,507-10,359-35,538-17,026-13,637-12,196-14,468-14,195-10,243-10,659-12,577------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-27.3%9.0013.0019.0031.0050.0068.0058.0069.0081.0094.0011012012578.0094.0010912271.0082.00
  Current Assets-27.3%9.0013.0018.0027.0046.0064.0057.0068.0080.0094.0010912012477.0094.0010812168.0080.00
    Cash Equivalents-29.0%9.0013.0017.0025.0034.0045.0024.0026.0034.0043.0072.0011412176.0092.0010511867.0079.00
  Net PPE-40.0%0.000.001.001.001.001.001.001.001.000.000.000.000.000.001.001.001.001.001.00
Liabilities-4.1%12.0012.0015.0038.0041.0038.0036.0033.0033.0033.0034.0031.0032.0031.0034.0035.0032.0033.0034.00
  Current Liabilities-3.0%12.0012.0014.0022.0017.0013.0010.008.0012.0010.008.005.0011.007.008.009.007.006.007.00
  Long Term Debt----15.0022.0023.0025.0025.0020.0021.0025.0025.0020.0023.0025.0025.0025.0025.0025.00
    LT Debt, Current----6.003.002.00--6.004.00--5.002.00-----
    LT Debt, Non Current----15.0022.0023.0025.0025.0020.0021.0025.00--------
Shareholder's Equity58150.9%4231.004.003889.0030.0022.0036.0048.0062.0075.0089.0093.0047.0060.0074.0090.008.007.00
  Retained Earnings-0.8%-425-422-418-395-377-356-337-319-303-287-272-257-244-231-216-200-183-168-157
  Additional Paid-In Capital0.1%4234234233883873863593553523493483463382782762752738.007.00
Shares Outstanding0.0%3.003.003.002.002.002.002.002.002.002.002.001.001.00------
Float-----68.00---101---107---107--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-72.5%-8,800-5,100-15,488-10,154-35,500-16,862-13,637-12,217-14,222-14,145-10,063-10,659-12,518-16,531-13,381-12,134-13,250-12,197-7,570-7,476-7,541
  Share Based Compensation-20.6%4285395309505941,5091,4711,6671,6771,4281,3601,3721,9561,5991,5021,6781,5071,137881819710
Cashflow From Investing-100.0%-525-19.0010,1707,61213,1608,2304,7714,438-14,392-32,864-3,196-59.00--34.00-36.00--47.00-173--125
Cashflow From Financing100.0%--27.007,279-301-58.0025,3182,890-403675-4.004546,59258,381-113-38564,391-45363,76427.00-

AXLA Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:    
Research and development$ 1,224$ 16,866$ 2,657$ 30,410
General and administrative2,3193,7535,0698,539
Total operating expenses3,54320,6197,72638,949
Loss from operations(3,543)(20,619)(7,726)(38,949)
Other (expense) income:    
Interest income1326527287
Interest expense0(752)0(1,456)
Other income (expense), net(2)065(27)
Total other income (expense), net130(687)337(1,396)
Net loss$ (3,413)$ (21,306)$ (7,389)$ (40,345)
Net loss per share, basic (USD per share)$ (0.05)$ (0.40)$ (0.10)$ (0.86)
Net loss per share, diluted (USD per share)$ (0.05)$ (0.40)$ (0.10)$ (0.86)
Weighted average common shares outstanding, basic (in shares)73,688,55852,616,27973,678,88147,052,105
Weighted average common shares outstanding, diluted (in shares)73,688,55852,616,27973,678,88147,052,105
Comprehensive loss:    
Net loss$ (3,413)$ (21,306)$ (7,389)$ (40,345)
Other comprehensive income (loss):    
Unrealized losses on marketable securities040(14)
Comprehensive loss$ (3,413)$ (21,302)$ (7,389)$ (40,359)

AXLA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 8,884$ 17,147
Prepaid expenses and other current assets383876
Total current assets9,26718,023
Property and equipment, net15693
Other assets0211
Total assets9,28218,927
Current liabilities:  
Accounts payable8,3954,707
Accrued expenses and other current liabilities1,7547,849
Current portion of operating lease liability1,3911,592
Total current liabilities11,54014,148
Operating lease liability0569
Other non-current liabilities046
Total liabilities11,54014,763
Commitments and contingencies (Note 8)00
Stockholders' equity (deficit):  
Common stock, $0.001 par value; 150,000,000 shares authorized, 74,111,726 and 74,074,201 shares issued and 73,692,745 and 73,655,220 shares outstanding at June 30, 2023 and December 31, 2022, respectively7474
Additional paid-in capital423,484422,517
Treasury stock, 418,981 shares at cost00
Accumulated deficit(425,816)(418,427)
Total stockholders' equity (deficit)(2,258)4,164
Total liabilities and stockholders' equity (deficit)$ 9,282$ 18,927
AXLA
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.axcellahealth.com
 EMPLOYEES11

Axcella Health Inc Frequently Asked Questions


What is the ticker symbol for Axcella Health Inc? What does AXLA stand for in stocks?

AXLA is the stock ticker symbol of Axcella Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axcella Health Inc (AXLA)?

As of Fri Dec 29 2023, market cap of Axcella Health Inc is 1.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXLA stock?

You can check AXLA's fair value in chart for subscribers.

What is the fair value of AXLA stock?

You can check AXLA's fair value in chart for subscribers. The fair value of Axcella Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axcella Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axcella Health Inc a good stock to buy?

The fair value guage provides a quick view whether AXLA is over valued or under valued. Whether Axcella Health Inc is cheap or expensive depends on the assumptions which impact Axcella Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXLA.

What is Axcella Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 29 2023, AXLA's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 8.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXLA PE ratio will change depending on the future growth rate expectations of investors.